Tumor markers (advances and limits).
Autor(a) principal: | |
---|---|
Data de Publicação: | 1997 |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2376 |
Resumo: | The author reviews and discusses the clinical utility of the major tumor markers. In spite of advances in the analytical systems, until recently there were no tumor markers that detect early stage cancer or that were absolutely specific or diagnostic for malignancy. Most of them are normal glycoproteins (that accompany the genetic deregulation of carcinogenesis) which are released into the blood and depend on liver function for their catabolism. Therefore such assays are of no use for screening healthy populations and a normal value does not exclude cancer. Their use may be of great help to the clinician in a number of ways: (1) primary staging of patients known to have cancer; (2) screening of high-risk individuals for the presence of some malignancies; (3) monitoring of the effectiveness of therapy; (4) patient's follow-up for early detection of relapses or metastases; (5) prognostic indexes; and (6) immunodetection of metastatic sites. Whatever the applications, a good clinical judgement is crucial for the use of these assays, with a critical look at the extent to which they contribute to a favorable outcome. At present, we think that their use in check-up studies should be avoided. |
id |
RCAP_b38aa5e93380717a853f39150ee8c9b3 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/2376 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Tumor markers (advances and limits).Marcadores tumorais (alcances e limites).The author reviews and discusses the clinical utility of the major tumor markers. In spite of advances in the analytical systems, until recently there were no tumor markers that detect early stage cancer or that were absolutely specific or diagnostic for malignancy. Most of them are normal glycoproteins (that accompany the genetic deregulation of carcinogenesis) which are released into the blood and depend on liver function for their catabolism. Therefore such assays are of no use for screening healthy populations and a normal value does not exclude cancer. Their use may be of great help to the clinician in a number of ways: (1) primary staging of patients known to have cancer; (2) screening of high-risk individuals for the presence of some malignancies; (3) monitoring of the effectiveness of therapy; (4) patient's follow-up for early detection of relapses or metastases; (5) prognostic indexes; and (6) immunodetection of metastatic sites. Whatever the applications, a good clinical judgement is crucial for the use of these assays, with a critical look at the extent to which they contribute to a favorable outcome. At present, we think that their use in check-up studies should be avoided.The author reviews and discusses the clinical utility of the major tumor markers. In spite of advances in the analytical systems, until recently there were no tumor markers that detect early stage cancer or that were absolutely specific or diagnostic for malignancy. Most of them are normal glycoproteins (that accompany the genetic deregulation of carcinogenesis) which are released into the blood and depend on liver function for their catabolism. Therefore such assays are of no use for screening healthy populations and a normal value does not exclude cancer. Their use may be of great help to the clinician in a number of ways: (1) primary staging of patients known to have cancer; (2) screening of high-risk individuals for the presence of some malignancies; (3) monitoring of the effectiveness of therapy; (4) patient's follow-up for early detection of relapses or metastases; (5) prognostic indexes; and (6) immunodetection of metastatic sites. Whatever the applications, a good clinical judgement is crucial for the use of these assays, with a critical look at the extent to which they contribute to a favorable outcome. At present, we think that their use in check-up studies should be avoided.Ordem dos Médicos1997-01-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2376oai:ojs.www.actamedicaportuguesa.com:article/2376Acta Médica Portuguesa; Vol. 10 No. 1 (1997): Janeiro; 75-80Acta Médica Portuguesa; Vol. 10 N.º 1 (1997): Janeiro; 75-801646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2376https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2376/1791Gomes, F Rinfo:eu-repo/semantics/openAccess2022-12-20T11:00:25Zoai:ojs.www.actamedicaportuguesa.com:article/2376Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:42.379361Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Tumor markers (advances and limits). Marcadores tumorais (alcances e limites). |
title |
Tumor markers (advances and limits). |
spellingShingle |
Tumor markers (advances and limits). Gomes, F R |
title_short |
Tumor markers (advances and limits). |
title_full |
Tumor markers (advances and limits). |
title_fullStr |
Tumor markers (advances and limits). |
title_full_unstemmed |
Tumor markers (advances and limits). |
title_sort |
Tumor markers (advances and limits). |
author |
Gomes, F R |
author_facet |
Gomes, F R |
author_role |
author |
dc.contributor.author.fl_str_mv |
Gomes, F R |
description |
The author reviews and discusses the clinical utility of the major tumor markers. In spite of advances in the analytical systems, until recently there were no tumor markers that detect early stage cancer or that were absolutely specific or diagnostic for malignancy. Most of them are normal glycoproteins (that accompany the genetic deregulation of carcinogenesis) which are released into the blood and depend on liver function for their catabolism. Therefore such assays are of no use for screening healthy populations and a normal value does not exclude cancer. Their use may be of great help to the clinician in a number of ways: (1) primary staging of patients known to have cancer; (2) screening of high-risk individuals for the presence of some malignancies; (3) monitoring of the effectiveness of therapy; (4) patient's follow-up for early detection of relapses or metastases; (5) prognostic indexes; and (6) immunodetection of metastatic sites. Whatever the applications, a good clinical judgement is crucial for the use of these assays, with a critical look at the extent to which they contribute to a favorable outcome. At present, we think that their use in check-up studies should be avoided. |
publishDate |
1997 |
dc.date.none.fl_str_mv |
1997-01-30 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2376 oai:ojs.www.actamedicaportuguesa.com:article/2376 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2376 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/2376 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2376 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2376/1791 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 10 No. 1 (1997): Janeiro; 75-80 Acta Médica Portuguesa; Vol. 10 N.º 1 (1997): Janeiro; 75-80 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130630056837120 |